ClinicalTrials.gov
public full text
Public Domain
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through complementary and synergistic mechanisms of actions.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease#918411
- Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates#1339589
- PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care#152581
- Efficacy and Safety of Dapagliflozin in Children With Proteinuria#1229680
- Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome#1339215
Record · ID 1279746
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive